Safety evaluation of the single-dose Ad26. COV2.S vaccine among healthcare workers in the Sisonke study in South Africa : a phase 3b implementation trial

Safety evaluation of the single-dose Ad26. COV2.S vaccine among healthcare workers in the Sisonke study in South Africa : a phase 3b implementation trial

Takuva, Simbarashe G.; Takalani, Azwidhwi; Seocharan, shen; Yende-Zuma, Nonhlanhla; Reddy, Tarylee; Engelbrecht, Imke; Faesen, Mark; Khuto, Kentse; Whyte, Carmen J.; Bailey, Veronique; Trivella, Valentina; Peter, Jonathan; Opie, Jessica; Louw, Vernon; Rowji, Pradeep; Jacobson, Barry; Groenewald, Pamela; Dorrington, Rob E.; Laubscher, Ria; Bradshaw, Debbie; Moultrie, Harry; Fairall, Lara; Sanne, Ian; GailBekker, Linda; Gray, Glenda; Goga, Ameena Ebrahim; Garrett, Nigel
URI: https://repository.up.ac.za/handle/2263/88106
Date: 2022-06-21

Abstract:

Real-world evaluation of the safety profile of vaccines after licensure is crucial to accurately characterise safety beyond clinical trials, support continued use, and thereby improve public confidence. The Sisonke study aimed to assess the safety and effectiveness of the Janssen Ad26.COV2.S vaccine among healthcare workers (HCWs) in South Africa. Here, we present the safety data.

Show full item record

Files in this item

Icon
Name: Takuva_Safety_2022.pdf
Size: 849.4Kb
Format: PDF
Description: Article
View/Open

This item appears in the following Collection(s)